Serum fibroblast growth factor-23 and risk of incident stroke and dementia: The Atherosclerosis Risk in Communities Study

Background Elevated concentrations of fibroblast growth factor 23 (FGF23), a hormone involved in bone mineral and vitamin D metabolism, may be associated with risk of stroke and dementia through inflammation, endothelial dysfunction, vessel calcification and stiffness, and axonal degeneration. Objective We tested the hypothesis that elevated FGF23 is associated with increased risk of dementia and stroke. Methods FGF23 was measured in serum samples collected in 1990–1992 from 12,391 participants of the Atherosclerosis Risk in Communities study. Participants were followed through 2019 for incident stroke and dementia. Cox regression was used to examine the associations of FGF23 (in quintiles) with risk of stroke and dementia, with adjustment for demographics, cardiovascular and dementia risk factors, and kidney function. Results Participants (mean 56.9 years; 57% female) were followed a median of 24 years; 1183 developed stroke and 2402 developed dementia. Participants in the highest versus lowest quintile of serum FGF23 were at elevated risk of stroke [HR (95% CI): 1.27 (1.06–1.51)] and dementia [HR: 1.21 (1.06–1.38)] independent of baseline demographics. Associations attenuated with additional adjustment for traditional cardiovascular risk factors [HR stroke : 1.20 (1.00–1.45); HR dementia : 1.17 (1.03–1.35)], and became even weaker after accounting for eGFR [HR stroke : 1.13 (0.94–1.37); HR dementia : 1.14 (1.00–1.31)]. The associations of FGF23 with incident stroke and dementia were not modified by categories of age, sex, race, or eGFR. Conclusions Higher FGF23 was associated with modestly greater risk of stroke and dementia in this population-based sample, though the association was largely attenuated after adjustment for traditional cardiovascular risk factors and kidney function.

Authors

Institutions

Publication Details

Journal
Journal of Alzheimer s Disease
Published
2026-11-21
DOI
https://doi.org/10.1177/13872877261507035
Primary Topic
Parathyroid Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Serum fibroblast growth factor-23 and risk of incident stroke and dementia: The Atherosclerosis Risk in Communities Study

Álvaro Alonso, Elizabeth Selvin, Erin D. Michos, Rebecca F. Gottesman et al.
Journal of Alzheimer s Disease
Parathyroid Disorders and Treatments
article

Serum fibroblast growth factor-23 and risk of incident stroke and dementia: The Atherosclerosis Risk in Communities Study

Álvaro Alonso, Elizabeth Selvin, Erin D. Michos, Rebecca F. Gottesman, Casey M. Rebholz, Pamela L. Lutsey, Sanaz Sedaghat, Kunihiro Matsushita, Devon M. Sauerer
article en

Abstract

Background Elevated concentrations of fibroblast growth factor 23 (FGF23), a hormone involved in bone mineral and vitamin D metabolism, may be associated with risk of stroke and dementia through inflammation, endothelial dysfunction, vessel calcification and stiffness, and axonal degeneration. Objective We tested the hypothesis that elevated FGF23 is associated with increased risk of dementia and stroke. Methods FGF23 was measured in serum samples collected in 1990–1992 from 12,391 participants of the Atherosclerosis Risk in Communities study. Participants were followed through 2019 for incident stroke and dementia. Cox regression was used to examine the associations of FGF23 (in quintiles) with risk of stroke and dementia, with adjustment for demographics, cardiovascular and dementia risk factors, and kidney function. Results Participants (mean 56.9 years; 57% female) were followed a median of 24 years; 1183 developed stroke and 2402 developed dementia. Participants in the highest versus lowest quintile of serum FGF23 were at elevated risk of stroke [HR (95% CI): 1.27 (1.06–1.51)] and dementia [HR: 1.21 (1.06–1.38)] independent of baseline demographics. Associations attenuated with additional adjustment for traditional cardiovascular risk factors [HR stroke : 1.20 (1.00–1.45); HR dementia : 1.17 (1.03–1.35)], and became even weaker after accounting for eGFR [HR stroke : 1.13 (0.94–1.37); HR dementia : 1.14 (1.00–1.31)]. The associations of FGF23 with incident stroke and dementia were not modified by categories of age, sex, race, or eGFR. Conclusions Higher FGF23 was associated with modestly greater risk of stroke and dementia in this population-based sample, though the association was largely attenuated after adjustment for traditional cardiovascular risk factors and kidney function.

Journal of Alzheimer s Disease
University of Minnesota (US), Johns Hopkins University (US), Emory University (US), National Institute of Neurological Disorders and Stroke (US)
Parathyroid Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon